A statement released earlier today by Commerzbank AG about MorphoSys (ETR:MOR) ups the target price to 57.00EUR
- Updated: September 30, 2016
Yesterday MorphoSys (ETR:MOR) traded 0.00% even at 37.04EUR. MOR’s 50-day average is 0.00EUR and its two hundred day average is 0.00EUR. With the last stock price close up 0.00% relative to the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Volume of trade was down over the average, with 0 shares of MOR changing hands under the typical 42,448
In a report announced on 9/30/2016 Commerzbank AG bumped up the target of MorphoSys (ETR:MOR) to 57.00EUR indicating a possible upside of 0.54%.
Previously on Wednesday August 31, 2016, Commerzbank AG reported about MorphoSys (ETR:MOR) bumped up the target price from 0.00EUR to 57.00EUR that suggested an upside of 0.47%.
See Chart Below
MorphoSys has a 52 week low of 0.00EUR and a 52 week high of 0.00EUR MOR’s total market value is presently 0 EUR.
More About MorphoSys (ETR:MOR)
MorphoSys AG (MorphoSys) develops and commercializes antibodies for therapeutic applications. The Company's operating segments include Proprietary Development and Partnered Discovery. The Company develops new treatments for patients suffering from serious diseases. The Company has a total of approximately 100 individual therapeutic antibody programs, among which are in Phase III trials. MorphoSys has developed various technologies, which offer direct access to fully human antibodies for the treatment of diseases. The Company's technologies include HuCAL, which is a collection of billions of fully human antibodies and a system for their optimization, and Ylanthia, which is an antibody library in Fab format based on the concept for generating specific and fully human antibodies. It is evaluating the clinical development of approximately three cancer programs, including MOR208, MOR202 and MOR209/ES414.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.